

ASSESSING THE EFFECTIVENESS OF THE HAMILTON RATING SCALE FOR DEPRESSION IN PHARMACEUTICAL RESEARCH

Niranjan Babu Mudduluru^{*1}, Jyothi Basini², Harshitha Cherukupalli³

¹Department of Pharmacognosy, Seven Hills College of Pharmacy, Tirupati, A.P., India

²Department of Pharmacology, Seven Hills College of Pharmacy, Tirupati, A.P., India

³Department of Pharmacognosy, Seven Hills College of Pharmacy, Tirupati, A.P., India

Corresponding Author

Dr. M. Niranjan Babu

Professor, Department of Pharmacognosy, Seven Hills College of Pharmacy, Tirupati, A.P., India – 517561, Contact: 7702484513, Email: principal.cq@jntua.ac.in

ABSTRACT

The objective of this project, employing the HRSD, is to advance the comprehension, prevention, and management of depression among industrial workers, thereby promoting their mental health and well-being. The project seeks to pinpoint specific risk factors within industrial workplaces that contribute to depression among employees. Through HRSD assessments, alongside surveys or interviews, researchers intend to investigate factors such as job demands, organizational culture, interpersonal relationships at work, and exposure to hazardous working conditions. The project also aims to assess the prevalence of occupational burnout among employees in a pharmaceutical company and its correlation with depressive symptoms.

INTRODUCTION

The Hamilton Depression Rating Scale (HDRS), previously known as the Hamilton Rating Scale for Depression (HRSD), is a clinician-administered tool developed by Max Hamilton in 1960 to assess the severity of depression symptoms. Comprising 17 elements, each with specific questions and criteria, the scale allows clinicians to evaluate a patient's mood, guilt, agitation, sleep disturbances, and other psychological and physical indicators of depression. Higher scores indicate more pronounced symptoms, providing a quantitative measure of depression severity. It's important to note that while the HDRS is widely used in mental health assessments, it is one of several tools available for this purpose. Mental health professionals, clinical trials, and research projects frequently employ the HDRS to monitor changes in depression symptoms over time and gauge treatment effectiveness. Accurately assessing depression severity is crucial for diagnosing conditions and devising appropriate treatment plans in clinical and research settings. Developed by psychiatrist Max Hamilton, the HDRS has established itself as a reliable instrument in the ongoing effort to evaluate and understand depression symptoms[1].

Structure and Components

The Hamilton Depression Rating Scale comprises 17 carefully crafted items, each designed to capture various facets of the depression experience. These factors encompass a range of symptoms such as mood, guilt, insomnia, and physical manifestations, offering a

comprehensive view of the patient's psychological state. The scale's structured design ensures consistency across evaluations and enables clinicians to monitor changes in symptoms over time. A detailed examination of each item highlights Hamilton's profound understanding of the intricate nature of depression[2]. For instance, item 3 not only assesses the presence of guilt but also evaluates its intensity and impact on daily functioning. This capability to analyze and quantify nuanced aspects underscores its value as a critical tool in mental health assessments.

Clinical and Research Applications

The Hamilton Depression Rating Scale is extensively utilized in both clinical and research settings. In clinical practice, it aids healthcare professionals in diagnosing depression, assessing symptom severity, and devising personalized treatment plans. Its structured framework facilitates communication among healthcare providers and promotes standardized approaches to mental health assessment [3]. In research, the HDRS has been instrumental in advancing our understanding of depression and its treatment strategies. Research studies frequently employ this scale to gauge intervention effectiveness, generating quantitative data that supports evidence-based practices. The consistent use of the HDRS in research endeavors allows for comparisons between studies and meta-analyses, enhancing our collective knowledge of depression dynamics.

Criticism and Development

Despite its widespread use, the Hamilton Depression Rating Scale is not without criticism. Some argue that its reliance on clinician judgment introduces subjectivity, potentially impacting the assessment's reliability. Moreover, cultural and demographic factors may influence how specific items are interpreted, questioning the scale's universality. Acknowledging these critiques, researchers and clinicians have endeavored to refine and expand upon Hamilton's original work [4]. Modified versions of the scale have been proposed, incorporating additional items or adjusting scoring criteria to enhance sensitivity and specificity. As the field of psychiatry evolves, ongoing efforts to refine assessment tools and tailor them to diverse populations continue to shape the landscape of depression evaluation.

Historical Significance of the HRSD



To fully appreciate the Hamilton Depression Rating Scale, it is essential to explore its historical context and development. In the mid-20th century, as interest in psychiatry grew, there was a recognized need for standardized instruments to objectively measure mental disorders. Max Hamilton, driven by this intellectual environment, sought to create a tool that could systematically assess the severity of depression symptoms and illuminate the multifaceted nature of this prevalent mental illness. Influenced by prevailing psychiatric paradigms such as psychoanalysis and behaviorism, Hamilton's pioneering work provided a structured framework for evaluating the subjective experience of depression as psychiatry shifted towards empirical methods [5]. In doing so, Hamilton's scale addressed a significant gap




Methodology.

- **Study Design:** Prospective study
- **Study Location:** Maiva Pharma company in Hosur
- **Duration of Study:** 6 months
- **Study Population:** 500 individuals
- **Data Collection:** Collection of data using the Hamilton Depression Rating Scale

Results

Table 1 presents data from a study involving 500 employees, representing 100% of the study population [6]. Among them, 145 (29%) were in the 16-19 years age group. Of the total employees, 255 (51%) were male and 245 (49%) were female, indicating a higher proportion of male employees [7]. Regarding symptoms, the majority of employees experienced Mild Depression (209/45%) [8]. In terms of designation, Others (212/42%) outnumbered Officers (8/2%) [9].





CONCLUSION

This study utilized the Hamilton Depression Rating Scale to measure depression, which has been shown to diminish patients' quality of life, affecting both physical functioning and psychological well-being. Depression can also lead to a heightened desire for hastened death and decisions to reject or discontinue potentially life-prolonging medical treatments. Despite efforts to identify and treat depression in terminally ill patients, challenges persist regarding distinguishing stable factors reflecting anxiety, depressed mood, insomnia, and somatic symptoms. Future research using the Hamilton Depression Rating Scale should explore whether all seventeen items are essential or if redundant items could be eliminated to prevent unnecessary inflation of depression severity scores during assessments.

REFERENCES

- [1] Williams JB: Standardizing the Hamilton Depression Rating Scale: past, present, and future. *Eur Arch Psychiatry Clin Neurosci* 2001; 251(suppl 2):II6–II12
- [2] Aben I, Verhey F, Lousberg R, Lodder J, Honig A: Validity of the Beck Depression Inventory, Hospital Anxiety and Depression Scale, SCL-90, and Hamilton Depression Rating Scale as screening instruments for depression in stroke patients. *Psychosomatics* 2002; 43:386–393
- [3] Akdemir A, Turkcapar MH, Orsel SD, Demiregi N, Dag I, Ozbay MH: Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. *Compr Psychiatry* 2001; 42:161–165
- [4] Baca-Garcia E, Blanco C, Saiz-Ruiz J, Rico F, Diaz-Sastre C, Cicchetti DV et al., Assessment of reliability in the clinical evaluation of depressive symptoms among multiple investigators in a multi-center clinical trial. *Psychiatry Res* 2001; 102:163–173
- [5] Bech P, Tanghøj P, Andersen HF, Overo K et al., Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. *Psychopharmacology (Berl)* 2002; 163:20–25
- [6] Entsuah R, Shaffer M, Zhang J: A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects. *J Psychiatr Res* 2002; 36:437–448
- [7] Faries D, Herrera J, Rayamajhi J, DeBrotta D, Demitrack M, Potter WZ: The responsiveness of the Hamilton Depression Rating Scale. *J Psychiatr Res* 2000; 34:3–10
- [8] Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW: The validity of the Hamilton and Montgomery-Åsberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. *Int J Geriatr Psychiatry* 2000; 15:644–649
- [9] Meyer JS, Li YS, Thornby J: et al., Validating mini-mental status, cognitive capacity screening and Hamilton depression scales utilizing subjects with vascular headaches. *Int J Geriatr Psychiatry* 2001; 16:430–435